Department of Mother and Child, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
PhD Program in Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Italy.
Front Endocrinol (Lausanne). 2022 Jun 22;13:896640. doi: 10.3389/fendo.2022.896640. eCollection 2022.
There is growing evidence of the role of epigenetic regulation of growth, and miRNAs potentially play a role.
The aim of this study is to identify changes in circulating miRNAs following GH treatment in subjects with isolated idiopathic GH deficiency (IIGHD) after the first 3 months of treatment, and verify whether these early changes can predict growth response.
The expression profiles of 384 miRNAs were analyzed in serum in 10 prepubertal patients with IIGHD (5 M, 5 F) at two time points before starting GH treatment (t-3, t0), and at 3 months on treatment (t+3). MiRNAs with a fold change (FC) >+1.5 or <-1.5 at t+3 were considered as differentially expressed. analysis of target genes and pathways led to a validation step on 8 miRNAs in 25 patients. Clinical and biochemical parameters were collected at baseline, and at 6 and 12 months. Simple linear regression analysis and multiple stepwise linear regression models were used to explain the growth response.
Sixteen miRNAs were upregulated and 2 were downregulated at t+3 months. MiR-199a-5p ( = 0.020), miR-335-5p ( = 0.001), and miR-494-3p ( = 0.026) were confirmed to be upregulated at t+3. Changes were independent of GH peak values at testing, and levels stabilized after 12 months. The predicted growth response at 12 months was considerably improved compared with models using the common clinical and biochemical parameters.
MiR-199a-5p, miR-335-5p, and miR-494-3p changed after 3 months of GH treatment and likely reflected both the degree of GH deficiency and the sensitivity to treatment. Furthermore, they were of considerable importance to predict growth response.
越来越多的证据表明表观遗传调控在生长中的作用,miRNA 可能发挥作用。
本研究旨在鉴定生长激素(GH)治疗后第 3 个月时孤立性特发性 GH 缺乏症(IIGHD)患者循环 miRNA 的变化,并验证这些早期变化是否可预测生长反应。
在开始 GH 治疗前的 2 个时间点(t-3、t0)和治疗后 3 个月(t+3),分析 10 例青春期前 IIGHD 患者(5 男,5 女)血清中 384 个 miRNA 的表达谱。t+3 时 FC>+1.5 或<-1.5 的 miRNA 被认为是差异表达的。对靶基因和途径进行分析后,在 25 例患者中对 8 个 miRNA 进行验证。收集基线时以及治疗后 6 个月和 12 个月的临床和生化参数。采用简单线性回归分析和多元逐步线性回归模型来解释生长反应。
16 个 miRNA 在 t+3 时上调,2 个 miRNA 下调。miR-199a-5p( = 0.020)、miR-335-5p( = 0.001)和 miR-494-3p( = 0.026)在 t+3 时被证实上调。这些变化与检测时 GH 峰值无关,且在 12 个月后稳定。与使用常规临床和生化参数的模型相比,12 个月时预测的生长反应得到了显著改善。
miR-199a-5p、miR-335-5p 和 miR-494-3p 在 GH 治疗 3 个月后发生变化,可能反映了 GH 缺乏的程度和对治疗的敏感性。此外,它们对预测生长反应具有重要意义。